A Phase 3 interventional study of Delgocitinib and Cream vehicle in Chronic Hand Eczema, sponsored by LEO Pharma. Completed at 37 sites in 7 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Eczema by LEO Pharma — 1 open to participants now, 1 under way, none of them phase 3. Eczema · LEO Pharma.
Among the 13 studies in Eczema by LEO Pharma, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2022, is one of 7 in phase 3, and was the 10th registered.
506 studies on the registry are indexed under Eczema; 90 are open to participants now.
Browse Eczema studies →1 of the 13 studies in Eczema by LEO Pharma is open now, in 1 country. Recruiting first, the newest first:
LEO Pharma · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is close to the median of 91 across 403 interventional studies indexed under Eczema.
Median enrollment 178 across the 12 interventional studies, 1,000 across the 1 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Eczema by LEO Pharma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to test if delgocitinib cream is effective in treating chronic hand eczema (CHE) and to find out what side effects it may have compared with a cream vehicle with no active medical ingredient in adolescents aged 12-17 years. At each visit to the clinic, the doctor will assess the severity and extent of CHE, and during the trial, the adolescents will assess their CHE signs and symptoms as well as quality of life.
The trial will last up to 22 weeks and has a 1-4 week screening period, a 16-week treatment period and a 2- week follow-up period. During the treatment period, each adolescent participant will use either the delgocitinib cream or cream vehicle twice daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects who have a documented recent history of inadequate response to treatment with topical (TCS) (at any time within 1 year before the screening visit) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks).
Exclusion Criteria:
Any disorder which is not stable and could:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Delgocitinib cream 20 mg/g twice daily
Drug: Delgocitinib
Cream vehicle twice daily
Drug: Cream vehicle
Cream for topical application
The cream vehicle is similar to the delgocitinib cream except that it does not contain any active medical ingredient.
Number of Participants With IGA-CHE Treatment Success at Week 16
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.
Time frame: Week 16
Number of Participants With HECSI-90 at Week 16
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline.
Time frame: Week 16
Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 16
The Hand Eczema Symptom Diary© (HESD) is an instrument designed to assess severity of CHE signs and symptoms. The participants will assess the worst severity of 6 individual signs and symptoms of CHE from 0 (none) to 10 (severe) over the past 24 hours. The participants will complete the HESD on a daily basis in an eDiary.' This endpoint will only assess the 'itch' component for participants with a baseline HESD itch score (weekly average) of ≥4 points.
Time frame: Week 16
Number of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 16
The Hand Eczema Symptom Diary© (HESD) is an instrument designed to assess severity of CHE signs and symptoms. The participants will assess the worst severity of 6 individual signs and symptoms of CHE from 0 (none) to 10 (severe) over the past 24 hours. The participants will complete the HESD on a daily basis in an eDiary.' This endpoint will only assess the 'pain' component for participants with a baseline HESD pain score (weekly average) of ≥4 points.
Time frame: Week 16
Number of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 16
The Hand Eczema Symptom Diary© (HESD) is an instrument designed to assess severity of CHE signs and symptoms. The participants will assess the worst severity of 6 individual signs and symptoms of CHE from 0 (none) to 10 (severe) over the past 24 hours. The participants will complete the HESD on a daily basis in an eDiary.' The final HESD score is an average of these 6 individual scores. This endpoint will only assess the score for participants with a baseline HESD itch score (weekly average) of ≥4 points.
Time frame: Week 16
Number of Participants With IGA-CHE Treatment Success at Week 2
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.
Time frame: Week 2
Number of Participants With IGA-CHE Treatment Success at Week 4
The Investigator's Global Assessment for chronic hand eczema© (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.
Time frame: Week 4
Number of Participants With IGA-CHE Treatment Success at Week 8
The Investigator's Global Assessment for chronic hand eczema© (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.
Time frame: Week 8
Number of Participants With IGA-CHE Treatment Success at Week 12
The Investigator's Global Assessment for chronic hand eczema© (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.
Time frame: Week 12
Change in CDLQI Score From Baseline to Week 16
The Children's Dermatology Life Quality Index (CDLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. Each question is scored from 0 (no impact) to 3 (high impact). The CDLQI score is the sum of the 10 items (score ranging from 0 to 30); a high score is indicative of a poor quality of life.
Time frame: Week 16
Number of Treatment Emergent AEs From Baseline up to Week 18
An adverse event (AE) will be considered treatment emergent if started after the first application of treatment, or started before the first application of treatment and worsened in severity after treatment.
Time frame: Week 18
This trial was conducted at sites in 7 countries (Australia, Belgium, Canada, Spain, France, United Kingdom, and Poland).
| Milestone | Delgocitinib Cream | Cream Vehicle |
|---|---|---|
| Started | 74 | 24 |
| Completed | 71 | 21 |
| Not completed | 3 | 3 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Lack of efficacy | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.
| Participants | Delgocitinib Cream | Cream Vehicle |
|---|---|---|
| Number of Participants With IGA-CHE Treatment Success at Week 16 | 47 | 7 |
The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline.
| Participants | Delgocitinib Cream | Cream Vehicle |
|---|---|---|
| Number of Participants With HECSI-90 at Week 16 | 53 | 9 |
The Hand Eczema Symptom Diary© (HESD) is an instrument designed to assess severity of CHE signs and symptoms. The participants will assess the worst severity of 6 individual signs and symptoms of CHE from 0 (none) to 10 (severe) over the past 24 hours. The participants will complete the HESD on a daily basis in an eDiary.' This endpoint will only assess the 'itch' component for participants with a baseline HESD itch score (weekly average) of ≥4 points.
| Participants | Delgocitinib Cream | Cream Vehicle |
|---|---|---|
| Number of Participants With Reduction of HESD Itch Score (Weekly Average) of ≥4 Points From Baseline at Week 16 | 35 | 7 |
The Hand Eczema Symptom Diary© (HESD) is an instrument designed to assess severity of CHE signs and symptoms. The participants will assess the worst severity of 6 individual signs and symptoms of CHE from 0 (none) to 10 (severe) over the past 24 hours. The participants will complete the HESD on a daily basis in an eDiary.' This endpoint will only assess the 'pain' component for participants with a baseline HESD pain score (weekly average) of ≥4 points.
| Participants | Delgocitinib Cream | Cream Vehicle |
|---|---|---|
| Number of Participants With Reduction of HESD Pain Score (Weekly Average) of ≥4 Points From Baseline at Week 16 | 31 | 5 |
The Hand Eczema Symptom Diary© (HESD) is an instrument designed to assess severity of CHE signs and symptoms. The participants will assess the worst severity of 6 individual signs and symptoms of CHE from 0 (none) to 10 (severe) over the past 24 hours. The participants will complete the HESD on a daily basis in an eDiary.' The final HESD score is an average of these 6 individual scores. This endpoint will only assess the score for participants with a baseline HESD itch score (weekly average) of ≥4 points.
| Participants | Delgocitinib Cream | Cream Vehicle |
|---|---|---|
| Number of Participants With Reduction of HESD Score (Weekly Average) of ≥4 Points From Baseline at Week 16 | 30 | 5 |
The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.
| Participants | Delgocitinib Cream | Cream Vehicle |
|---|---|---|
| Number of Participants With IGA-CHE Treatment Success at Week 2 | 16 | 1 |
The Investigator's Global Assessment for chronic hand eczema© (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.
| Participants | Delgocitinib Cream | Cream Vehicle |
|---|---|---|
| Number of Participants With IGA-CHE Treatment Success at Week 4 | 28 | 4 |
The Investigator's Global Assessment for chronic hand eczema© (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.
| Participants | Delgocitinib Cream | Cream Vehicle |
|---|---|---|
| Number of Participants With IGA-CHE Treatment Success at Week 8 | 36 | 9 |
The Investigator's Global Assessment for chronic hand eczema© (IGA-CHE) is a 5 point scale used in clinical trials to rate the severity of the subject's CHE from 0 (clear) to 4 (severe). Treatment success means a score of 0 (clear) or 1 (almost clear) with a ≥2 step improvement from baseline.
| Participants | Delgocitinib Cream | Cream Vehicle |
|---|---|---|
| Number of Participants With IGA-CHE Treatment Success at Week 12 | 43 | 6 |
The Children's Dermatology Life Quality Index (CDLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. Each question is scored from 0 (no impact) to 3 (high impact). The CDLQI score is the sum of the 10 items (score ranging from 0 to 30); a high score is indicative of a poor quality of life.
| score on a scale | Delgocitinib Cream | Cream Vehicle |
|---|---|---|
| Change in CDLQI Score From Baseline to Week 16 | -5.57 ± 0.44 | -2.92 ± 0.78 |
An adverse event (AE) will be considered treatment emergent if started after the first application of treatment, or started before the first application of treatment and worsened in severity after treatment.
| events | Delgocitinib Cream | Cream Vehicle |
|---|---|---|
| Number of Treatment Emergent AEs From Baseline up to Week 18 | 77 | 19 |
Collected over Treatment emergent adverse events were collected during the 16 weeks of treatment + 2 weeks of follow-up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Delgocitinib Cream | 0/74 (0%) | 0/74 (0%) | 17/74 (23%) |
| Cream Vehicle | 0/24 (0%) | 0/24 (0%) | 4/24 (16.7%) |
| Event | Delgocitinib Cream | Cream Vehicle |
|---|---|---|
| NasopharyngitisInfections and infestations | 10/74 | 4/24 |
| Upper respiratory tract infectionInfections and infestations | 5/74 | 0/24 |
| HeadacheNervous system disorders | 4/74 | 1/24 |
| Age, Categorical(Participants) | Delgocitinib Cream | Cream Vehicle | Total |
|---|---|---|---|
| <=18 years | 74 | 24 | 98 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Delgocitinib Cream | Cream Vehicle | Total |
|---|---|---|---|
| Mean | 14.6 ± 1.7 | 14.7 ± 1.6 | 14.6 ± 1.7 |
| Sex: Female, Male(Participants) | Delgocitinib Cream | Cream Vehicle | Total |
|---|---|---|---|
| Female | 46 | 12 | 58 |
| Male | 28 | 12 | 40 |
| Ethnicity (NIH/OMB)(Participants) | Delgocitinib Cream | Cream Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 0 | 8 |
| Not Hispanic or Latino | 62 | 21 | 83 |
| Unknown or Not Reported | 4 | 3 | 7 |
| Race (NIH/OMB)(Participants) | Delgocitinib Cream | Cream Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 69 | 20 | 89 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 4 |
| Region of Enrollment(participants) | Delgocitinib Cream | Cream Vehicle | Total |
|---|---|---|---|
| Canada | 6 | 1 | 7 |
| Belgium | 2 | 0 | 2 |
| Poland | 23 | 9 | 32 |
| United Kingdom | 5 | 2 | 7 |
| Australia | 10 | 4 | 14 |
| France | 11 | 5 | 16 |
| Spain | 17 | 3 | 20 |
| IGA-CHE score(Participants) | Delgocitinib Cream | Cream Vehicle | Total |
|---|---|---|---|
| Clear | 0 | 0 | 0 |
| Almost clear | 0 | 0 | 0 |
| Mild | 0 | 0 | 0 |
| Moderate | 56 | 18 | 74 |
| Severe | 18 | 6 | 24 |
| HECSI score(scores on a scale) | Delgocitinib Cream | Cream Vehicle | Total |
|---|---|---|---|
| Mean | 70.9 ± 37.8 | 76.2 ± 39.7 | 72.2 ± 38.1 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Dec 2024, 28 months.
Results were first posted in Jul 2025, 6 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Eczema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 26. This study's 28 months is above that.
Counting every sponsor, half of 71 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delgocitinib